2021 Annual Meeting | C41 - Update in Movement Disorders 3: Update on Clinical Trials in Parkinson’s and Huntington’s Diseases

Date Monday 04/19/21

Time 08:00 AM - 09:00 AM EDT Add To Calendar

Session Format This program will be presented both in-person and online

On Demand This program will be available in the meeting's On Demand product.

Event Type Seminar

Director(s) Tanya Simuni, MD, FAAN

Moderator(s) Jacinda B. Sampson, MD, PhD

Topic(s) Movement Disorders

Learning Objectives Participants should become familiar with the recently completed and on-going PD clinical trials. Participants should become familiar with the criteria to identify patients most appropriate for PD disease modifying interventions. Participants should become familiar with the with the recently completed and on-going HD clinical trials

CME Available 1.00 CME credit

Core Competencies Medical Knowledge, Practice-based Learning and Improvement, Systems-based Practice

Program Level Introductory

Program Tracks Advanced Practice Provider

Recommended Audience Fellow, Resident, General Neurologist, Specialist Neurologist, Non-neurologist, Advanced Practice Provider, Neurohospitalist, Medical Student

Teaching Styles Didactic

Program Materials Program Evaluations

Event Timeline
08:00 AM - 08:30 AM EDT	Speaker	Overview of PD Experimental Therapeutics: Focus on Disease Modification Trials Tanya Simuni, MD, FAAN
08:30 AM - 08:50 AM EDT	Speaker	Update on Clinical Trials in Huntington's Disease Tiago Mestre, MD, MSC
08:50 AM - 09:00 AM EDT	Q&A	Live Q&A Tanya Simuni, MD, FAAN, Tiago Mestre, MD, MSC

Faculty Disclosures
Tanya Simuni, MD, FAAN	Dr. Simuni has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for cadia, AcureX, Adamas, AskBio, Amneal, Blue Rock Therapeutics, Caraway Therapeutics, Critical Path for Parkinson's Consortium (CPP), Denali, Michael J Fox Foundation, Neuroderm, Sanofi, Sinopia, Roche, Takeda and Vanqua Bio. Dr. Simuni has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for of Koneksa, Neuroderm, Sanofi, UCB, AcureX, Adamas, AskBio, Biohaven, Denali, GAIN, Neuron23 and Roche. Dr. Simuni has received research support from Amneal, Biogen, Neuroderm, Prevail, Roche, and UCB and an investigator for NINDS, MJFF, Parkinson's Foundation.
Tiago Mestre, MD, MSC	Dr. Mestre has received personal compensation in the range of $500-$4,999 for serving as a Consultant for CHDI. Dr. Mestre has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for PTC. Dr. Mestre has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Abbvie. Dr. Mestre has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Ipsen. Dr. Mestre has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Abbvie. Dr. Mestre has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Abbvie. The institution of Dr. Mestre has received research support from CIHR. The institution of Dr. Mestre has received research support from Ontario Research Fund. The institution of Dr. Mestre has received research support from MJFF. The institution of Dr. Mestre has received research support from Parkinson Canada. The institution of Dr. Mestre has received research support from University of Ottawa/PRC.
Jacinda B. Sampson, MD, PhD	Dr. Sampson has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Dyne Therapeutics. Dr. Sampson has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Viking Therapeutics. Dr. Sampson has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Biogen. Dr. Sampson has received research support from Marigold Foundation. Dr. Sampson has a non-compensated relationship as a Scientific Advisory Committee with Myotonic Dystrophy Foundation that is relevant to AAN interests or activities.

��ɫ��

��ɫ��